| Market Cap | 138.09M | P/E | - | EPS this Y | 71.40% | Ern Qtrly Grth | - |
| Income | 20.86M | Forward P/E | -7.04 | EPS next Y | -133.30% | 50D Avg Chg | -5.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -23.00% |
| Dividend | N/A | Price/Book | 0.91 | EPS next 5Y | - | 52W High Chg | -75.00% |
| Recommedations | 3.00 | Quick Ratio | 40.92 | Shares Outstanding | 40.77M | 52W Low Chg | 91.00% |
| Insider Own | 11.45% | ROA | -4.72% | Shares Float | 35.03M | Beta | 1.76 |
| Inst Own | 16.51% | ROE | 12.70% | Shares Shorted/Prior | 354.40K/237.42K | Price | 3.45 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 864,170 | Target Price | 3.25 |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 460,205 | Change | 4.23% |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mayer Arie | Director Director | Apr 03 | Buy | 2.22 | 8,809 | 19,556 | 26,809 | 04/04/23 |
| KIDRON NADAV | President and CEO President and CEO | Mar 16 | Buy | 2.039 | 26,000 | 53,014 | 126,000 | 03/16/23 |
| KIDRON NADAV | President and CEO President and CEO | Mar 14 | Buy | 2.01 | 100,000 | 201,000 | 100,000 | 03/15/23 |
| Kidron Miriam | Chief Scientific Off.. Chief Scientific Officer | Mar 14 | Sell | 2.01 | 100,000 | 201,000 | 201,666 | 03/15/23 |
| Rozov Yadin | Director Director | Mar 13 | Buy | 2 | 70,000 | 140,000 | 86,500 | 03/15/23 |
| Rabinowitz Michael | Chief Commercial Off.. Chief Commercial Officer | Jan 03 | Sell | 12.75 | 13,325 | 169,894 | 126,143 | 01/04/23 |
| Mayer Arie | Director Director | Nov 01 | Sell | 25.60 | 3,000 | 76,800 | 05/10/22 | |
| RAKIN KEVIN | Director Director | Mar 21 | Sell | 9.4096 | 10,000 | 94,096 | 46,661 | 03/22/22 |
| RAKIN KEVIN | Director Director | Feb 17 | Option | 4.8 | 6,667 | 32,002 | 59,671 | 02/22/22 |